Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC

Eur Heart J 2021;42:373–498; doi:10.1093/eurheartj/ehaa612

Amendments have been made to the originally published supplementary data of this manuscript.

Specifically:

• Supplementary Table 9, column ‘Edoxaban’, row ‘eGFR category’, ‘>95 mL/min’ (page 15). The cell should be coloured green instead of yellow. It should also read “60 mg” instead of “60 mg (use with caution in ‘supranormal’ renal function).”

• In the above-indicated cell, a footnote has also been added to state: “Edoxaban should be used in patients with high creatinine clearance only after a careful evaluation of the individual thromboembolic and bleeding risk.”

• Supplementary Table 9, column ‘Edoxaban’, row ‘Dose reduction in selected patients’ (page 16). The cell should read “Edoxaban 60 mg reduced to 30 mg once daily if any of the following: creatinine clearance 15-50 mL/min, body weight ≤60 kg, concomitant use of dronedarone, erythromycin, ciclosporine or ketokonazole” instead of “Edoxaban 60 mg reduced to 30 mg once daily, and edoxaban 30 mg reduced to 15mg once daily, if any of the following: creatinine clearance of 30-50 mL/min, body weight ≤60 kg, concomitant us of verapamil or quinidine or dronedarone.”

These have been corrected online.